- Home
- BATRK vs MLTX Comparison
BATRK vs MLTX Comparison
Compare BATRK & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATRK
- MLTX
- Stock Information
- Founded
- BATRK 1991
- MLTX 2021
- Country
- BATRK United States
- MLTX Switzerland
- Employees
- BATRK N/A
- MLTX N/A
- Industry
- BATRK Broadcasting
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- BATRK Industrials
- MLTX Health Care
- Exchange
- BATRK Nasdaq
- MLTX Nasdaq
- Market Cap
- BATRK 2.9B
- MLTX 2.8B
- IPO Year
- BATRK N/A
- MLTX N/A
- Fundamental
- Price
- BATRK $44.98
- MLTX $55.75
- Analyst Decision
- BATRK Strong Buy
- MLTX Strong Buy
- Analyst Count
- BATRK 3
- MLTX 7
- Target Price
- BATRK $58.00
- MLTX $74.83
- AVG Volume (30 Days)
- BATRK 250.5K
- MLTX 380.3K
- Earning Date
- BATRK 08-07-2025
- MLTX 08-05-2025
- Dividend Yield
- BATRK N/A
- MLTX N/A
- EPS Growth
- BATRK N/A
- MLTX N/A
- EPS
- BATRK N/A
- MLTX N/A
- Revenue
- BATRK $702,443,000.00
- MLTX N/A
- Revenue This Year
- BATRK $14.16
- MLTX N/A
- Revenue Next Year
- BATRK $3.97
- MLTX N/A
- P/E Ratio
- BATRK N/A
- MLTX N/A
- Revenue Growth
- BATRK 6.51
- MLTX N/A
- 52 Week Low
- BATRK $35.46
- MLTX $31.42
- 52 Week High
- BATRK $47.18
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- BATRK 54.00
- MLTX 59.35
- Support Level
- BATRK $44.52
- MLTX $53.29
- Resistance Level
- BATRK $45.30
- MLTX $56.78
- Average True Range (ATR)
- BATRK 0.71
- MLTX 2.07
- MACD
- BATRK 0.13
- MLTX -0.05
- Stochastic Oscillator
- BATRK 85.12
- MLTX 78.36
About BATRK Atlanta Braves Holdings Inc. Series C
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.